Type 1 diabetes Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Type 1 diabetes has traditionally been
diagnosed based on clinical catabolic symptoms suggestive of insulin
deficiency: polyuria, polydipsia, weight loss, and marked hyperglycemia that is
nonresponsive to oral agents. It is categorized as an autoimmune disease with
progressive b-cell destruction, resulting in a physiological dependence on
exogenous insulin. Recent studies have broadened our understanding of the
disease but have made diagnosis more complex. Type 1 diabetes care must be an
iterative process, adapted as the needs of the individual evolve. In children
and adults, clinical assessments for type 1 diabetes should incorporate
age-appropriate and complication-focused evaluations based on the possibility
that an abnormality will be present. A young adult with common cardiovascular
disease (CVD) risk and no complications may need more assessment of lifestyle
adjustment than an older adult with a long time of the disease who may need
more vascular and neurological issues evaluation.
- The prevalence rate of Type 1 diabetes varies from 0.06% to
0.1% among all the population in the USA.
Thelansis’s “Type 1 diabetes Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Type
1 diabetes treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Type 1 diabetes across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Type 1 diabetes Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment